Rasmussen PV, Dalgaard F, Gislason GH, et al. - Researchers investigated a dose–response relationship between amiodarone use and the risk of cancer in a large nationwide study cohort. They assessed 18,503 Danish patients (Median age: 70 years) with atrial fibrillation treated with amiodarone from 1996 to 2014 employing nationwide registers. Cancer development was reported in a total of 2,974 individuals during the median follow-up time of 8.1 years (interquartile range 4.3–12.4). Outcomes did not support the dose–response relationship between cumulative dose of amiodarone and incident cancer risk.